Philip Malinas, MD
Psychiatry · Reno, NVNPI 1700934825
Payments from drug & device makers
Across 1,070 payments — averaging $103.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$34K
- Teva Pharmaceuticals USA, Inc.$24K
- AbbVie$16K
- Alkermes, Inc.$13K
- Eisai Inc.$7K
- Ironshore Pharmaceuticals Inc.$6K
- plus $12K from 26 others
What the payments were for
- Consulting fees$8,8708%
- Speaking & faculty fees$74,27967%
- Travel & lodging$7,8717%
- Food & beverage$19,50818%
- Education$1750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$50,640
- Austedo XR$21,754
- ABILIFY MAINTENA$21,351
- VRAYLAR$12,982
- ARISTADA INITIO$12,660
- REXULTI$11,931
- Dayvigo$6,620
- Jornay PM 20mg capsules (Bottle of 100)$5,030
- LATUDA$942
- COBENFY$240
- NEUROSTAR TMS THERAPY$220
- ABILIFY MYCITE$175
- INGREZZA$125
- ABILIFY ASIMTUFII$123
- SPRAVATO$112
- Fanapt$105
- INVEGA SUSTENNA$104
- INVEGA TRINZA$104
How this compares
$110,704 in reported general payments places this provider in the 95th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 30 | $347,013 |
| VraylarCariprazine Hcl | 95 | $169,344 |
| CaplytaLumateperone Tosylate | 54 | $96,169 |
| Invega SustennaPaliperidone Palmitate | 17 | $55,116 |
| Lurasidone Hcl | 93 | $40,094 |
| LybalviOlanzapine/Samidorphan Malate | 23 | $39,153 |
| AuvelityDextromethorphan Hbr/Bupropion | 20 | $30,182 |
| TrintellixVortioxetine Hydrobromide | 31 | $16,692 |
| RexultiBrexpiprazole | 12 | $16,603 |
| QuviviqDaridorexant Hcl | 33 | $16,223 |
| Ziprasidone Hcl | 71 | $6,892 |
| Alprazolam | 436 | $4,807 |
| Clozapine | 55 | $4,612 |
| Chlorpromazine Hcl | 30 | $4,212 |
| Lisdexamfetamine Dimesylate | 16 | $3,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $23,769 | $347,01330 claims |
| AbbVieVraylar | $15,863 | $169,34495 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,355 | $96,16954 claims |
| Johnson & JohnsonInvega Sustenna | $800 | $55,11617 claims |
| Alkermes, Inc.Lybalvi | $13,276 | $39,15323 claims |
| Axsome Therapeutics, Inc.Auvelity | $128 | $30,18220 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $716 | $16,69231 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $33,769 | $16,60312 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $407 | $16,22333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 243 psychiatry providers in Nevada.
Other psychiatry in Reno
- Ekaterina StepanovaReno$208K
- Brian KirkpatrickReno$18K
- Nickolas CulpepperReno$8K
- Philip RichReno$6K
- Meekile MasonReno$6K
- Geraldine SteinagelReno$4K
- Kathleen StollReno$3K
- Steven HolroydReno$3K
- Jayleen ChenReno$2K
- Thomas BittkerReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.